CRISPR Gene Editing Breakthroughs

Scientists continue to refine CRISPR technology for therapeutic applications. Improved delivery via lipid nanoparticles and modified viral vectors has reduced off-target effects.

Clinical trials now target sickle cell disease, muscular dystrophy, and inherited retinal disorders with unprecedented precision.

Ethical considerations are becoming more prominent as the technology moves from laboratory to clinic. Regulatory frameworks are adapting to balance innovation with patient safety.